ATF4 promotes bone angiogenesis by increasing vegf expression and release in the bone environment

Journal of Bone and Mineral Research

Volumn 28, Issue 9, 2013, Pages 1870-1884

  Zhu, Ke ^a,b   Jiao, Hongli ^a,b   Li, Shuai ^a   Cao, Huiling ^c   Galson, Deborah L ^c   Zhao, Zhongfang ^a   Zhao, Xi ^a   Lai, Yumei ^b   Fan, Jie ^d   Im, Hee Jeong ^b   Chen, Di ^b   Xiao, Guozhi ^b  

^a NANKAI UNIVERSITY   (China)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

ANGIOGENESIS; ATF4; BONE; OSTEOBLASTS; OSTEOCLASTS; VEGF

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN KINASE C; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE; BONE DEVELOPMENT; BONE MATRIX; CONTROLLED STUDY; ENDOTHELIAL SPROUTING; ENDOTHELIUM; ENZYME BINDING; ENZYME DEGRADATION; ENZYME INDUCTION; GENE DELETION; GENE EXPRESSION; HYPOXIA; METATARSAL BONE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STABILITY; REOXYGENATION; TRABECULAR BONE; UBIQUITINATION; VASCULARIZATION;

ANGIOGENESIS; ATF4; BONE; OSTEOBLASTS; OSTEOCLASTS; VEGF;

ACTIVATING TRANSCRIPTION FACTOR 4; ANIMALS; BONE AND BONES; BONE MATRIX; BONE RESORPTION; CELL HYPOXIA; ENDOTHELIUM; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; METATARSAL BONES; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOBLASTS; OSTEOCLASTS; OXYGEN; PROLYL HYDROXYLASES; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTEIN KINASE C; PROTEIN STABILITY; RNA STABILITY; RNA, MESSENGER; UBIQUITINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84882734356     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1958     Document Type: Article

References (61)

1. Schipani E, Maes C, Carmeliet G, Semenza GL., Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. J Bone Miner Res. 2009; 24 (8): 1347-53.
2. Maes C, Carmeliet P, Moermans K, Stockmans I, Smets N, Collen D, Bouillon R, Carmeliet G., Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev. 2002; 111 (1-2): 61-73.
3. Wang Y, Wan C, Deng L, Liu X, Cao X, Gilbert SR, Bouxsein ML, Faugere MC, Guldberg RE, Gerstenfeld LC, Haase VH, Johnson RS, Schipani E, Clemens TL., The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest. 2007; 117 (6): 1616-26.
4. Wan C, Gilbert SR, Wang Y, Cao X, Shen X, Ramaswamy G, Jacobsen KA, Alaql ZS, Eberhardt AW, Gerstenfeld LC, Einhorn TA, Deng L, Clemens TL., Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci USA. 2008; 105 (2): 686-91.
5. Jacobsen KA, Al-Aql ZS, Wan C, Fitch JL, Stapleton SN, Mason ZD, Cole RM, Gilbert SR, Clemens TL, Morgan EF, Einhorn TA, Gerstenfeld LC., Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res. 2008; 23 (5): 596-609.
6. Street J, Bao M, deGuzman L, Bunting S, Peale FV Jr, Ferrara N, Steinmetz H, Hoeffel J, Cleland JL, Daugherty A, van Bruggen N, Redmond HP, Carano RA, Filvaroff EH., Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci USA. 2002; 99 (15): 9656-61.
7. Liu Y, Berendsen AD, Jia S, Lotinun S, Baron R, Ferrara N, Olsen BR., Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest. 2012; 122 (9): 3101-13.
8. Maes C, Kobayashi T, Kronenberg HM., A novel transgenic mouse model to study the osteoblast lineage in vivo. Ann NY Acad Sci. 2007; 1116: 149-64.
9. Cackowski FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD, Windle JJ, Blair HC, Roodman GD., Osteoclasts are important for bone angiogenesis. Blood. 2010; 115 (1): 140-9.
10. Bruni-Cardoso A, Johnson LC, Vessella RL, Peterson TE, Lynch CC., Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Mol Cancer Res. 2010; 8 (4): 459-70.
11. Huang LE, Pete EA, Schau M, Milligan J, Gu J., Leu-574 of HIF-1alpha is essential for the von Hippel-Lindau (VHL)-mediated degradation pathway. J Biol Chem. 2002; 277 (44): 41750-5.
12. Huang LE, Gu J, Schau M, Bunn HF., Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 1998; 95 (14): 7987-92.
13. Bruick RK., Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev. 2003; 17 (21): 2614-23.
14. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ., The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399 (6733): 271-5.
15. Kaelin WG Jr., Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002; 2 (9): 673-82.
16. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, Poellinger L., Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. EMBO J. 1998; 17 (22): 6573-86.
17. Mahon PC, Hirota K, Semenza GL., FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001; 15 (20): 2675-86.
18. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK., FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002; 16 (12): 1466-71.
19. Wenger RH, Stiehl DP, Camenisch G., Integration of oxygen signaling at the consensus HRE. Sci STKE. 2005; 306: re12.
20. Powis G, Kirkpatrick L., Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther. 2004; 3 (5): 647-54.
21. Karpinski BA, Morle GD, Huggenvik J, Uhler MD, Leiden JM., Molecular cloning of human CREB-2: an ATF/CREB transcription factor that can negatively regulate transcription from the cAMP response element. Proc Natl Acad Sci USA. 1992; 89 (11): 4820-4.
22. Tsujimoto A, Nyunoya H, Morita T, Sato T, Shimotohno K., Isolation of cDNAs for DNA-binding proteins which specifically bind to a tax-responsive enhancer element in the long terminal repeat of human T-cell leukemia virus type I. J Virol. 1992; 65 (3): 1420-6.
23. Gaikwad JS, Cavender A, D'Souza RN., Identification of tooth-specific downstream targets of Runx2. Gene. 2001; 279 (1): 91-7.
24. Meyer TE, Habener JF., Cyclic adenosine 3',5'-monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins. Endocr Rev. 1993; 14 (3): 269-90.
25. Sassone-Corsi P., Goals for signal transduction pathways: linking up with transcriptional regulation. Embo J. 1994; 13 (20): 4717-28.
26. Ziff EB., Transcription factors: a new family gathers at the cAMP response site. Trends Genet. 1990; 6 (3): 69-72.
27. Brindle PK, Montminy MR., The CREB family of transcription activators. Curr Opin Genet Dev. 1992; 2 (2): 199-204.
28. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, Li L, Brancorsini S, Sassone-Corsi P, Townes TM, Hanauer A, Karsenty G., ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell. 2004; 117 (3): 387-98.
29. Zhang X, Yu S, Galson DL, Luo M, Fan J, Zhang J, Guan Y, Xiao G., Activating transcription factor 4 is critical for proliferation and survival in primary bone marrow stromal cells and calvarial osteoblasts. J Cell Biochem. 2008; 105 (3): 885-95.
30. Yang X, Karsenty G., ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells. J Biol Chem. 2004; 279 (45): 47109-14.
31. Yu S, Franceschi RT, Luo M, Zhang X, Jiang D, Lai Y, Jiang Y, Zhang J, Xiao G., Parathyroid hormone increases activating transcription factor 4 expression and activity in osteoblasts: requirement for osteocalcin gene expression. Endocrinology. 2008; 149 (4): 1960-8.
32. Yu S, Jiang Y, Galson DL, Luo M, Lai Y, Lu Y, Ouyang HJ, Zhang J, Xiao G., General transcription factor IIA-gamma increases osteoblast-specific osteocalcin gene expression via activating transcription factor 4 and runt-related transcription factor 2. J Biol Chem. 2008; 283 (9): 5542-53.
33. Yu S, Franceschi RT, Luo M, Fan J, Jiang D, Cao H, Kwon TG, Lai Y, Zhang J, Patrene K, Hankenson K, Roodman GD, Xiao G., Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone. PLoS One. 2009; 4 (10): e7583.
34. Xiao G, Jiang D, Ge C, Zhao Z, Lai Y, Boules H, Phimphilai M, Yang X, Karsenty G, Franceschi RT., Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression. J Biol Chem. 2005; 280 (35): 30689-96.
35. Cao H, Yu S, Yao Z, Galson DL, Jiang Y, Zhang X, Fan J, Lu B, Guan Y, Luo M, Lai Y, Zhu Y, Kurihara N, Patrene K, Roodman GD, Xiao G., Activating transcription factor 4 regulates osteoclast differentiation in mice. J Clin Invest. 2010; 120 (8): 2755-66.
36. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G., Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005; 434 (7032): 514-20.
37. Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, Parada LF, Karsenty G., ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab. 2006; 4 (6): 441-51.
38. Roybal CN, Hunsaker LA, Barbash O, Vander Jagt DL, Abcouwer SF., The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism. J Biol Chem. 2005; 280 (21): 20331-9.
39. Afonyushkin T, Oskolkova OV, Philippova M, Resink TJ, Erne P, Binder BR, Bochkov VN., Oxidized phospholipids regulate expression of ATF4 and VEGF in endothelial cells via NRF2-dependent mechanism: novel point of convergence between electrophilic and unfolded protein stress pathways. Arterioscler Thromb Vasc Biol. 2010; 30 (5): 1007-13.
40. Ghosh R, Lipson KL, Sargent KE, Mercurio AM, Hunt JS, Ron D, Urano F., Transcriptional regulation of VEGF-A by the unfolded protein response pathway. PLoS One. 2010; 5 (3): e9575.
41. Dedieu S, Canron X, Rezvani HR, Bouchecareilh M, Mazurier F, Sinisi R, Zanda M, Moenner M, Bikfalvi A, North S., The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A. BMC Med. 2010; 8: 19.
42. Pereira ER, Liao N, Neale GA, Hendershot LM., Transcriptional and post-transcriptional regulation of proangiogenic factors by the unfolded protein response. PLoS One. 2010; 5 (9): e12521.
43. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M, Candinas D., HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J. 2001; 15 (13): 2445-53.
44. Yang S, Xu H, Yu S, Cao H, Fan J, Ge C, Fransceschi RT, Dong HH, Xiao G., Foxo1 mediates insulin-like growth factor 1 (IGF1)/insulin regulation of osteocalcin expression by antagonizing Runx2 in osteoblasts. J Biol Chem. 2011; 286 (21): 19149-58.
45. Banerjee C, McCabe LR, Choi JY, Hiebert SW, Stein JL, Stein GS, Lian JB., Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. J Cell Biochem. 1997; 66 (1): 1-8.
46. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G., Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation [see comments]. Cell. 1997; 89 (5): 747-54.
47. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T., Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts [see comments]. Cell. 1997; 89 (5): 755-64.
48. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, Owen MJ, Mertelsmann R, Zabel BU, Olsen BR., Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia [see comments]. Cell. 1997; 89 (5): 773-9.
49. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ., Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development [see comments]. Cell. 1997; 89 (5): 765-71.
50. Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT., Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res. 1999; 14 (6): 893-903.
51. Xiao G, Cui Y, Ducy P, Karsenty G, Franceschi RT., Ascorbic acid-dependent activation of the osteocalcin promoter in MC3T3-E1 preosteoblasts: requirement for collagen matrix synthesis and the presence of an intact OSE2 sequence. Mol Endocrinol. 1997; 11 (8): 1103-13.
52. Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ., Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Res. 2009; 69 (5): 1836-43.
53. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93 (2): 165-76.
54. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998; 95 (7): 3597-602.
55. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ., Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89 (2): 309-19.
56. Moroz E, Carlin S, Dyomina K, Burke S, Thaler HT, Blasberg R, Serganova I., Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One. 2009; 4 (4): e5077.
57. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, Zhao L, Nagy TR, Peng X, Hu J, Feng X, Van Hul W, Wan M, Cao X., TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009; 15 (7): 757-65.
58. Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA., Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One. 2009; 4 (9): e6896.
59. Brighton CT, Krebs AG., Oxygen tension of healing fractures in the rabbit. J Bone Joint Surg Am. 1972; 54 (2): 323-32.
60. Maurer P, Meyer L, Eckert AW, Berginski M, Schubert J., Measurement of oxygen partial pressure in the mandibular bone using a polarographic fine needle probe. Int J Oral Maxillofac Surg. 2006; 35 (3): 231-6.
61. Kolar P, Gaber T, Perka C, Duda GN, Buttgereit F., Human early fracture hematoma is characterized by inflammation and hypoxia. Clin Orthop Relat Res. 2011; 469 (11): 3118-26.